MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.

Financial Strength

9/10

Name	Current	Vs Industry
Cash-To-Debt	0.83
Equity-to-Asset	0.63
Debt-to-Equity	0.29
Debt-to-EBITDA	0.83
Interest Coverage	15.26
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	8.51	Distress Grey Safe
Beneish M-Score	-2.57	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	23.3
	3-Year EBITDA Growth Rate	27.7
	3-Year EPS without NRI Growth Rate	38
	3-Year FCF Growth Rate	26
	3-Year Book Growth Rate	19.7

Momentum Rank

9/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	48.51
	9-Day RSI	49.96
	14-Day RSI	50.96
	6-1 Month Momentum %	6.96
	12-1 Month Momentum %	80.83

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.63
	Quick Ratio	1.83
	Cash Ratio	0.87
	Days Inventory	136.19
	Days Sales Outstanding	57.95
	Days Payable	105.23

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Shareholder Yield %	-0.05

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	58.96
	Operating Margin %	15.78
	Net Margin %	12.74
	FCF Margin %	13.99
	ROE %	20.97
	ROA %	12.92
	ROIC %	17.62
	ROC (Joel Greenblatt) %	50.7
	ROCE %	21.56
	Years of Profitability over Past 10-Year	10

GF Value Rank

3/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	34.25
	PE Ratio without NRI	34.25
	Shiller PE Ratio	99.34
	Price-to-Owner-Earnings	25.65
	PEG Ratio	1.21
	PS Ratio	4.37
	PB Ratio	6.5
	Price-to-Tangible-Book	13.83
	Price-to-Free-Cash-Flow	31.22
	Price-to-Operating-Cash-Flow	25.36
	EV-to-EBIT	26.82
	EV-to-EBITDA	19.68
	EV-to-Revenue	4.59
	EV-to-FCF	31.23
	Price-to-Projected-FCF	3.15
	Price-to-DCF (Earnings Based)	0.82
	Price-to-DCF (FCF Based)	1.09
	Price-to-Median-PS-Value	1.81
	Price-to-Peter-Lynch-Fair-Value	1.37
	Price-to-Graham-Number	4.59
	Price-to-Net-Current-Asset-Value	45.24
	Earnings Yield (Greenblatt) %	3.72
	FCF Yield %	3.07
	Forward Rate of Return (Yacktman) %	21.42

Financials (Next Earnings Date:2025-01-31)

Annual Quarterly TTM

FRA:61MA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

No Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

No Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

No Enough Data

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

No Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015

MedCap AB Executives

Details

GF Value: €34.92

FRA:61MA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with 61MA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	158.541
	EPS (TTM) (€)	1.356
	Beta	1.33
	Volatility %	35.61
	14-Day RSI	50.96
	14-Day ATR (€)	1.112475
	20-Day SMA (€)	47.0025
	12-1 Month Momentum %	80.83
	52-Week Range (€)	25.95 - 52.6
	Shares Outstanding (Mil)	14.81

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

MedCap AB Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

MedCap AB Stock Events

Financials Calendars

	Event	Date	Price(€)
No Event Data

MedCap AB Frequently Asked Questions

What is MedCap AB(FRA:61MA)'s stock price today?

The current price of FRA:61MA is €46.60. The 52 week high of FRA:61MA is €52.60 and 52 week low is €25.95.

When is next earnings date of MedCap AB(FRA:61MA)?

The next earnings date of MedCap AB(FRA:61MA) is 2025-01-31.

Does MedCap AB(FRA:61MA) pay dividends? If so, how much?

MedCap AB(FRA:61MA) does not pay dividend.

Press Release

	Subject	Date
No Press Release

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.